131 related articles for article (PubMed ID: 36588020)
1. Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer.
Chin CP; Smith WH; Cesaretti J; Terk M; Garden EB; Araya JS; Palese MA; Stock RG; Buckstein M
Urol Oncol; 2023 Jun; 41(6):296.e9-296.e16. PubMed ID: 36588020
[TBL] [Abstract][Full Text] [Related]
2. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
3. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
4. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
5. Does muscle invasive bladder cancer following pelvic radiotherapy portend worse prognosis? A seer-based study.
Natale C; Leinwand G; Zeineddine F; Silberstein JL; Krane LS
Cancer Treat Res Commun; 2020; 24():100177. PubMed ID: 32454387
[TBL] [Abstract][Full Text] [Related]
6. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
7. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
8. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
Miyajima K; Suzuki H; Urabe F; Iwatani K; Imai Y; Yasue K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Koike Y; Miki J; Yuen S; Sasaki T; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
Int J Clin Oncol; 2023 Sep; 28(9):1200-1206. PubMed ID: 37432614
[TBL] [Abstract][Full Text] [Related]
10. Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality.
Keehn A; Ludmir E; Taylor J; Rabbani F
World J Urol; 2017 May; 35(5):713-720. PubMed ID: 27629559
[TBL] [Abstract][Full Text] [Related]
11. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.
Hathout L; Folkert MR; Kollmeier MA; Yamada Y; Cohen GN; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):312-9. PubMed ID: 25304791
[TBL] [Abstract][Full Text] [Related]
12. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer.
Yee DS; Shariat SF; Lowrance WT; Sterbis JR; Vora KC; Bochner BH; Donat SM; Herr HW; Dalbagni G; Sandhu JS
J Urol; 2010 May; 183(5):1751-6. PubMed ID: 20299035
[TBL] [Abstract][Full Text] [Related]
13. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
Guo X; Liu M; Hou H; Liu S; Zhang X; Zhang Y; Wu P; Pang C; Wang J
Int J Clin Oncol; 2019 Aug; 24(8):957-965. PubMed ID: 30903422
[TBL] [Abstract][Full Text] [Related]
14. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
[TBL] [Abstract][Full Text] [Related]
15. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
16. The risk of second malignancies after
Fernandez Ots A; Browne L; Chin YS; Malouf D; Wong K; Bucci J
Brachytherapy; 2016; 15(6):752-759. PubMed ID: 27475483
[TBL] [Abstract][Full Text] [Related]
17. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
18. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
19. Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancer.
Ozawa Y; Yagi Y; Nakamura K; Hattori S; Nishiyama T; Momma T; Yorozu A; Saito S
Brachytherapy; 2022; 21(4):451-459. PubMed ID: 35461773
[TBL] [Abstract][Full Text] [Related]
20. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Parry MG; Nossiter J; Sujenthiran A; Cowling TE; Patel RN; Morris M; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1219-1229. PubMed ID: 33279595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]